Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses’ Health Study and Nurses’ Health Study II
- 191 Downloads
Findings from epidemiologic studies of oxidative stress biomarkers and breast cancer have been mixed, although no studies have focused on estrogen receptor-negative (ER−) tumors which may be more strongly associated with oxidative stress. We examined prediagnostic plasma fluorescent oxidation products (FlOP), a global biomarker of oxidative stress, and risk of ER− breast cancer in a nested case-control study in the Nurses’ Health Study and Nurses’ Health Study II. ER− breast cancer cases (n = 355) were matched to 355 controls on age, month/time of day of blood collection, fasting status, menopausal status, and menopausal hormone use. Conditional logistic regression models were used to examine associations of plasma FlOP at three emission wavelengths (FlOP_360, FlOP_320, and FlOP_400) and risk of ER− breast cancer. We did not observe any significant associations between FlOP measures and risk of ER− breast cancer overall; the RRQ4vsQ1 (95 %CI) 0.70 (0.43–1.13), p trend = 0.09 for FlOP_360; 0.91(0.56-1.46), p trend = 0.93 for FlOP_320; and 0.62 (0.37-1.03), p trend = 0.10 for FlOP_400. Results were similar in models additionally adjusted for total carotenoid levels and in models stratified by age and total carotenoids. Although high (vs. low) levels of FIOP_360 and FIOP_400 were associated with lower risk of ER− breast cancer in lean women (body mass index (BMI) < 25 kg/m2) but not in overweight/obese women, these differences were not statistically significant (pint = 0.23 for FlOP_360; pint = 0.37 for FlOP_400). Our findings suggest that positive associations of plasma FlOP concentrations and ER− breast cancer risk are unlikely.
KeywordsFluorescent oxidation products Oxidative stress Breast cancer Estrogen receptor
This research was supported from the NIH RO1 CA131218, NHS and NHSII UM1: CA186107 and CA176726. KA Hirko was supported by the R25 CA098566 and the T32 CA009001 training grants. RT Fortner was supported by the T32 CA009001 training grant. We would like to thank the participants and staff of the Nurses’ Health Study and the Nurses’ Health Study II for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflicts of interest. The analysis presented here complies with current laws of the country in which they were performed.
- 11.Rossner P Jr, Gammon MD, Terry MB, Agrawal M, Zhang FF, Teitelbaum SL, Eng SM, Gaudet MM, Neugut AI, Santella RM (2006) Relationship between urinary 15-F2t-isoprostane and 8-oxodeoxyguanosine levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev 15(4):639–644. doi: 10.1158/1055-9965.epi-05-0554 CrossRefPubMedGoogle Scholar
- 13.Dai Q, Gao YT, Shu XO, Yang G, Milne G, Cai Q, Wen W, Rothman N, Cai H, Li H, Xiang Y, Chow WH, Zheng W (2009) Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women’s Health Study. J Clin Oncol 27(15):2482–2488. doi: 10.1200/jco.2008.19.7970 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Lee KH, Shu XO, Gao YT, Ji BT, Yang G, Blair A, Rothman N, Zheng W, Chow WH, Kang D (2010) Breast cancer and urinary biomarkers of polycyclic aromatic hydrocarbon and oxidative stress in the Shanghai Women’s Health Study. Cancer Epidemiol Biomarkers Prev 19(3):877–883. doi: 10.1158/1055-9965.epi-09-1098 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Sisti JS, Lindstrom S, Kraft P, Tamimi RM, Rosner BA, Wu T, Willett WC, Eliassen AH (2015) Premenopausal plasma carotenoids, fluorescent oxidation products, and subsequent breast cancer risk in the nurses’ health studies. Breast Cancer Res Treat 151(2):415–425. doi: 10.1007/s10549-015-3391-6 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Eliassen AH, Hendrickson SJ, Brinton LA, Buring JE, Campos H, Dai Q, Dorgan JF, Franke AA, Gao YT, Goodman MT, Hallmans G, Helzlsouer KJ, Hoffman-Bolton J, Hulten K, Sesso HD, Sowell AL, Tamimi RM, Toniolo P, Wilkens LR, Winkvist A, Zeleniuch-Jacquotte A, Zheng W, Hankinson SE (2012) Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. J Natl Cancer Inst 104(24):1905–1916. doi: 10.1093/jnci/djs461 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Zhang X, Spiegelman D, Baglietto L, Bernstein L, Boggs DA, van den Brandt PA, Buring JE, Gapstur SM, Giles GG, Giovannucci E, Goodman G, Hankinson SE, Helzlsouer KJ, Horn-Ross PL, Inoue M, Jung S, Khudyakov P, Larsson SC, Lof M, McCullough ML, Miller AB, Neuhouser ML, Palmer JR, Park Y, Robien K, Rohan TE, Ross JA, Schouten LJ, Shikany JM, Tsugane S, Visvanathan K, Weiderpass E, Wolk A, Willett WC, Zhang SM, Ziegler RG, Smith-Warner SA (2012) Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies. Am J Clin Nutr 95(3):713–725. doi: 10.3945/ajcn.111.014415 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Hirko KA, Spiegelman D, Willett WC, Hankinson SE, Eliassen AH (2014) Alcohol consumption in relation to plasma sex hormones, prolactin, and sex hormone-binding globulin in premenopausal women. Cancer Epidemiol Biomarkers Prev 23(12):2943–2953. doi: 10.1158/1055-9965.epi-14-0982 CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Mahalingaiah PK, Ponnusamy L, Singh KP (2015) Chronic oxidative stress causes estrogen-independent aggressive phenotype, and epigenetic inactivation of estrogen receptor alpha in MCF-7 breast cancer cells. Breast Cancer Res Treat 153(1):41–56. doi: 10.1007/s10549-015-3514-0 CrossRefPubMedGoogle Scholar